Cargando…
The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a fatal infection, but no clinical case due to AP92 strain was reported. We described the first clinical case due to AP92 like CCHFV. METHODS: A case infected by a AP92 like CCHFV was detected in Balkanian part of Turkey. Diagnosis was confirmed...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700115/ https://www.ncbi.nlm.nih.gov/pubmed/19515251 http://dx.doi.org/10.1186/1471-2334-9-90 |
_version_ | 1782168578444754944 |
---|---|
author | Midilli, Kenan Gargılı, Ayşen Ergonul, Onder Elevli, Murat Ergin, Sevgi Turan, Nesrin Şengöz, Gönül Ozturk, Recep Bakar, Mehmet |
author_facet | Midilli, Kenan Gargılı, Ayşen Ergonul, Onder Elevli, Murat Ergin, Sevgi Turan, Nesrin Şengöz, Gönül Ozturk, Recep Bakar, Mehmet |
author_sort | Midilli, Kenan |
collection | PubMed |
description | BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a fatal infection, but no clinical case due to AP92 strain was reported. We described the first clinical case due to AP92 like CCHFV. METHODS: A case infected by a AP92 like CCHFV was detected in Balkanian part of Turkey. Diagnosis was confirmed by RT-PCR and sequencing. A human serologic and tick survey studies were performed in the region, where the case detected. RESULTS: Thirty eight individuals out of 741 were found to be anti CCHFV IgM positive. The attack rate for overall CCHFV was calculated as 5.2%. In univariate analyses, CCHFV IgM positivity was found to be associated with the age (p < 0.001), male gender (p = 0.001), agricultural activity (p = 0.036), and history of tick bite (p = 0.014). In multivariate analysis, older age (OR: 1.03, CI:1.01–1.05, p < 0.001), male gender were found to be the risk factors (OR: 2.5, CI:1.15–5.63, p = 0.020) for CCHFV infection. CONCLUSION: This is the first human case with AP92 like CCHFV infection. Furthermore, this is the first report of AP92 like strain in Turkey. In the region, elderly males carry the highest risk for CCHFV infection. |
format | Text |
id | pubmed-2700115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27001152009-06-23 The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey Midilli, Kenan Gargılı, Ayşen Ergonul, Onder Elevli, Murat Ergin, Sevgi Turan, Nesrin Şengöz, Gönül Ozturk, Recep Bakar, Mehmet BMC Infect Dis Research Article BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a fatal infection, but no clinical case due to AP92 strain was reported. We described the first clinical case due to AP92 like CCHFV. METHODS: A case infected by a AP92 like CCHFV was detected in Balkanian part of Turkey. Diagnosis was confirmed by RT-PCR and sequencing. A human serologic and tick survey studies were performed in the region, where the case detected. RESULTS: Thirty eight individuals out of 741 were found to be anti CCHFV IgM positive. The attack rate for overall CCHFV was calculated as 5.2%. In univariate analyses, CCHFV IgM positivity was found to be associated with the age (p < 0.001), male gender (p = 0.001), agricultural activity (p = 0.036), and history of tick bite (p = 0.014). In multivariate analysis, older age (OR: 1.03, CI:1.01–1.05, p < 0.001), male gender were found to be the risk factors (OR: 2.5, CI:1.15–5.63, p = 0.020) for CCHFV infection. CONCLUSION: This is the first human case with AP92 like CCHFV infection. Furthermore, this is the first report of AP92 like strain in Turkey. In the region, elderly males carry the highest risk for CCHFV infection. BioMed Central 2009-06-10 /pmc/articles/PMC2700115/ /pubmed/19515251 http://dx.doi.org/10.1186/1471-2334-9-90 Text en Copyright ©2009 Midilli et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Midilli, Kenan Gargılı, Ayşen Ergonul, Onder Elevli, Murat Ergin, Sevgi Turan, Nesrin Şengöz, Gönül Ozturk, Recep Bakar, Mehmet The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey |
title | The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey |
title_full | The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey |
title_fullStr | The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey |
title_full_unstemmed | The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey |
title_short | The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey |
title_sort | first clinical case due to ap92 like strain of crimean-congo hemorrhagic fever virus and a field survey |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700115/ https://www.ncbi.nlm.nih.gov/pubmed/19515251 http://dx.doi.org/10.1186/1471-2334-9-90 |
work_keys_str_mv | AT midillikenan thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT gargılıaysen thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT ergonulonder thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT elevlimurat thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT erginsevgi thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT turannesrin thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT sengozgonul thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT ozturkrecep thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT bakarmehmet thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT midillikenan firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT gargılıaysen firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT ergonulonder firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT elevlimurat firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT erginsevgi firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT turannesrin firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT sengozgonul firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT ozturkrecep firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey AT bakarmehmet firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey |